![A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma]()
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myelomaZhao, Wan-Hong; Liu, Jie; Wang, Bai-Yan; Chen, Yin-Xia; Cao, Xing-Mei; Yang, Yun; Zhang, Yi-Lin; Wang, Fang-Xia; Zhang, Peng-Yu; Lei, Bo; Gu, Liu-Fang; Wang, Jian-Li; Yang, Nan; Zhang, Ru; Zhang, Hui; Shen, Ying; Bai, Ju; Xu, Yan; Wang, Xu-Geng; Zhang, Rui-Li; Wei, Li-Li; Li, Zong-Fang; Li, Zhen-Zhen; Geng, Yan; He, Qian; Zhuang, Qiu-Chuan; Fan, Xiao-Hu; He, Ai-Li; Zhang, Wang-Gang · Journal of Hematology & Oncology · 2018